Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin

New England Journal of Medicine

Volumn 337, Issue 5, 1997, Pages 295-300

  Bolla, Michel ^a   Gonzalez, Dionisio ^b   Warde, Padraig ^c   Dubois, Jean Bernard ^d   Mirimanoff, René Olivier ^e   Storme, Guy ^f   Bernier, Jacques ^g   Kuten, Abraham ^h   Sternberg, Cora ⁱ   Gil, Thierry ^j   Collette, Laurence ^j   Pierart, Marianne ^j  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d Anticancer Center   (France)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f Oncologisch Centrum   (Belgium)

^g OSPEDALE SAN GIOVANNI   (Switzerland)

^h RAMBAM MEDICAL CENTER   (Israel)

ⁱ Ufficio Sternberg and Pansadoro   (Italy)

^j EORTC DATA CENTER   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; GONADORELIN AGONIST; GOSERELIN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GYNECOMASTIA; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; CYPROTERONE ACETATE; GOSERELIN; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0030856678     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199707313370502     Document Type: Article

References (19)

1. Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Stanford University. In: Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. National Cancer Institute monographs. No. 7. Washington, D.C.: Government Printing Office, 1988:47-60.
2. National Institutes of Health Consensus Development Panel. Consensus statement: the management of clinically localized prostate cancer. In: Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. National Cancer Institute monographs. No. 7. Washington, D.C.: Government Printing Office, 1988:3-6.
3. Hanks GE, Corn BW, Lee WR, Hunt M, Hanlon A, Schultheiss TE. External beam irradiation of prostate cancer: conformal treatment techniques and outcomes for the 1990s. Cancer 1995;75:1972-7.
4. Leibel SA, Fuks Z, Zelefsky MJ, Whitmore WF Jr. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 1994;28:7-16.
5. Schröder FH. What is new in endocrine therapy of prostatic cancer? In: Newling DWW, Jones WG, eds. EORTC Genitourinary Group monograph 7. Prostate cancer and testicular cancer. New York: Wiley-Liss, 1990:45-52.
6. van der Werf-Messing B, Sourek-Zikova V, Blonk DI. Localized advanced carcinoma of the prostate: radiation therapy versus hormonal therapy. Int J Radiat Oncol Biol Phys 1976;1:1043-8.
7. Neglia WJ, Hussey DH, Johnson DE. Megavoltage radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1977;2:873-83.
8. Taylor WJ, Richardson RG, Hafermann MD. Radiation therapy for localized prostate cancer. Cancer 1979;43:1123-7.
9. Fellows GJ, Clark PB, Beynon LL, et al. Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment: a Medical Research Council study. Br J Urol 1992;70:304-9.
10. ICRU report 29. Dose specification for reporting external beam therapy with photons and electrons. Washington, D.C.: International Commission on Radiation Units and Measurements, April 1, 1978.
11. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
12. Dusserre A, Garavaglia G, Giraud JY, Bolla M. Quality assurance of the EORTC radiotherapy trial 22863 for prostatic cancer: the dummy run. Radiother Oncol 1995;36:229-34.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
15. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
16. Pilepich MV, Krall JM, al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-23.
17. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy. Prog Proc Am Soc Clin Oncol 1995;14:239. abstract.
18. Scardino PT, Wheeler TM. Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. In: Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. National Cancer Institute monographs. No. 7. Washington, D.C.: Government Printing Office, 1988:95-103.
19. Rozan R, Albuisson E, Kin B, et al. External beam radiation of stage T3/T4 adenocarcinoma of the prostate. In: Bolla M, Rambeaud JJ, Vincent F, eds. Local prostatic carcinoma. Basel, Switzerland: Karger, 1994: 98-110.